

Author index

Volume 45 (1997)

- Allan Klock, P. 45, 63
Apfelbaum, J.L. 45, 63
- Babor, T.F. 45, 13, 93
Ball, C.E. 45, 105
Beratis, S. 45, 207
Berlin, I. 45, 31
Bigelow, G.E. 45, 81
Brooner, R.K. 45, 105
Budney, A.J. 45, 1
Burleson, J.A. 45, 157
- Carroll, M.E. 45, 21
Cherek, D.R. 45, 1
Cho, A.M. 45, 63
Coalson, D.W. 45, 63
Coiro, V. 45, 115
Creson, D.R. 45, 143
- Danjou, P. 45, 177
Dawes, M.A. 45, 165
Del Boca, F.K. 45, 13
Dewey, W.L. 45, 47
Dykstra, L.A. 45, 197
- E. Fantegrossi, W. 45, 71
Eissenberg, T. 45, 81
- Fendrich, M. 45, 185
Frosch, D. 45, 131
- Gazaway, P.M. 45, 105
Glowa, J.R. 45, 71
Golden, A.S. 45, 105
Goldstein, P.J. 45, 185
- Huggins, G.R. 45, 105
Hughes, C.E. 45, 197
- Johnson, R.E. 45, 81
- Kadden, R.M. 45, 93
Kandel, D.B. 45, 1
Kirisci, L. 45, 165
Klafta, J.M. 45, 63
Kokkevi, A. 45, 55
Kranzler, H.R. 45, 93, 157
- Launay, J.-M. 45, 31
Lekka, N.P. 45, 207
Leventakou, V. 45, 55
Liebson, I.A. 45, 81
Ling, W. 45, 131
- Mackesy-Amiti, M.E. 45, 185
Marks, S. 45, 63
Martin, B.R. 45, 1
Mattox, A.J. 45, 21
McCann, M.J. 45, 131
McCaul, M.E. 45, 105
McRee, B. 45, 13
Meisch, R.A. 45, 143
Miller, P. 45, 121
Miotto, K. 45, 131
- Palermou, B. 45, 55
Paschalis, C. 45, 207
Payan, C. 45, 177
Pickens, R.W. 45, 105
Puech, A.-J. 45, 177
- Rawson, R.A. 45, 131
Richardson, C. 45, 55
Roache, J.D. 45, 143
Rodefer, J.S. 45, 21
Roffman, R. 45, 1
Rosendale, C.T. 45, 105
Rounsaville, B.J. 45, 93
- Saïd, S. 45, 31
Shah, N.N. 45, 143
Skipsey, K. 45, 157
Smith, F.L. 45, 47
Spreux-Varoquaux, O. 45, 31
Stanley, M.A. 45, 143
Stephens, R.S. 45, 1
S. Thompson, S. 45, 21
Stitzer, M.L. 45, 81, 105
Strain, E.C. 45, 81
Svikis, D.S. 45, 105
- Tarter, R.E. 45, 165
Tennen, H. 45, 93
Toledano, A.Y. 45, 63
- Velez, M.L. 45, 105
Vescovi, P.P. 45, 115
- Walsh, S.L. 45, 81
Warot, D. 45, 177
Welch, S.P. 45, 39, 47
- Zacny, J.P. 45, 63

THE
LIBRARY
OF THE
UNIVERSITY OF
TORONTO

1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025

Subject index

Volume 45 (1997)

Addiction Research Center Inventory (ARCI); Healthy subjects; Amphetamine; Reliability; Sensitivity; Specificity; ROC analysis **45, 177**

Adolescents; Family structure; Illicit drugs; Smoking; Alcohol; Personality **45, 121**

Agonists; Cocaine; Self-administration; Replacement/substitution therapy; Drug reinforcement; Rhesus monkeys **45, 71**

Alcohol; Benzodiazepine; Caffeine; Cigarette smoking; Substance dependence **45, 207**

Alcohol; Family structure; Adolescents; Illicit drugs; Smoking; Personality **45, 121**

Alcoholism; Amenorrhea; Prolactin; Metoclopramide; TRH **45, 115**

Alcohol; Nitrous oxide; Reinforcing; Choice; Subjective; Mood; Psychomotor; Behavior; History; Human **45, 63**

Alcohol; Secondary analysis; Marijuana; Gateway drug; Prevention efforts **45, 185**

Alprazolam; Benzodiazepines; Anxiety; Panic; Reinforcement; Self-administration; Self-medication **45, 143**

Alternative reinforcer; Behavioral economics; Buprenorphine; Cocaine; Inhalation; Rhesus monkeys; Saccharin; Self-administration; Smoking **45, 21**

Amenorrhea; Alcoholism; Prolactin; Metoclopramide; TRH **45, 115**

Amphetamine; Addiction Research Center Inventory (ARCI); Healthy subjects; Reliability; Sensitivity; Specificity; ROC analysis **45, 177**

Anandamide; Δ^9 -THC; CP55,940; Dynorphins; Tolerance **45, 39**

Antagonist-precipitated withdrawal; Buprenorphine; Less-than-daily-dosing; Opioid antagonists; Physical dependence; Spontaneous withdrawal **45, 81**

Anxiety; Benzodiazepines; Alprazolam; Panic; Reinforcement; Self-administration; Self-medication **45, 143**

ATP-gated potassium channels; Morphine; Tolerance; Glyburide binding; CNS **45, 47**

AUDIT; Drug-dependent patients; Harmful drinking **45, 157**

Behavioral economics; Alternative reinforcer; Buprenorphine; Cocaine; Inhalation; Rhesus monkeys; Saccharin; Self-administration; Smoking **45, 21**

Behavioral self-regulation; Drug abuse; Etiology; Liability; Child development **45, 165**

Behavior; Nitrous oxide; Reinforcing; Choice; Subjective; Mood; Psychomotor; Alcohol; History; Human **45, 63**

Benzodiazepine; Alcohol; Caffeine; Cigarette smoking; Substance dependence **45, 207**

Benzodiazepines; Alprazolam; Anxiety; Panic; Reinforcement; Self-administration; Self-medication **45, 143**

Buprenorphine; Alternative reinforcer; Behavioral economics; Cocaine; Inhalation; Rhesus monkeys; Saccharin; Self-administration; Smoking **45, 21**

Buprenorphine; Less-than-daily-dosing; Opioid antagonists; Antagonist-precipitated withdrawal; Physical dependence; Spontaneous withdrawal **45, 81**

Caffeine; Alcohol; Benzodiazepine; Cigarette smoking; Substance dependence **45, 207**

Cannabinoid; Marijuana use; Dependence **45, 1**

Child development; Drug abuse; Etiology; Behavioral self-regulation; Liability **45, 165**

Choice; Nitrous oxide; Reinforcing; Subjective; Mood; Psychomotor; Alcohol; Behavior; History; Human **45, 63**

Cigarette smoking; Alcohol; Benzodiazepine; Caffeine; Substance dependence **45, 207**

CNS; Morphine; ATP-gated potassium channels; Tolerance; Glyburide binding **45, 47**

Cocaine; Alternative reinforcer; Behavioral economics; Buprenorphine; Inhalation; Rhesus monkeys; Saccharin; Self-administration; Smoking **45, 21**

Cocaine; Self-administration; Replacement/substitution therapy; Drug reinforcement; Agonists; Rhesus monkeys **45, 71**

Cost-Effectiveness; Pregnancy; Drug dependence; Treatment; Outcome **45, 105**

- CP55,940**; Anandamide; Δ^9 -THC; Dynorphins; Tolerance 45, 39
- Dependence**; Marijuana use; Cannabinoid 45, 1
- Dependent smokers**; Past history of depression; Monoamine oxidases; Withdrawal symptoms 45, 31
- Diagnosis**; Reliability; SCID; DSM-III-R 45, 13
- Diagnostic validity**; LEAD procedure; Substance abuse 45, 93
- Drug abuse**; Etiology; Behavioral self-regulation; Liability; Child development 45, 165
- Drug dependence**; Pregnancy; Treatment; Cost-Effectiveness; Outcome 45, 105
- Drug dependence**; Self reports; Reliability 45, 55
- Drug-dependent patients**; AUDIT; Harmful drinking 45, 157
- Drug reinforcement**; Cocaine; Self-administration; Replacement/substitution therapy; Agonists; Rhesus monkeys 45, 71
- DSM-III-R**; Reliability; Diagnosis; SCID 45, 13
- Dynorphins**; Anandamide; Δ^9 -THC; CP55,940; Tolerance 45, 39
- Etiology**; Drug abuse; Behavioral self-regulation; Liability; Child development 45, 165
- Family structure**; Adolescents; Illicit drugs; Smoking; Alcohol; Personality 45, 121
- Fixed-ratio schedule**; Meperidine; Morphine; β -Funaltrexamine; Naltrexone; Response-rate; Squirrel monkey 45, 197
- β -Funaltrexamine**; Meperidine; Morphine; Naltrexone; Response-rate; Fixed-ratio schedule; Squirrel monkey 45, 197
- Gateway drug**; Secondary analysis; Marijuana; Alcohol; Prevention efforts 45, 185
- Glyburide binding**; Morphine; ATP-gated potassium channels; Tolerance; CNS 45, 47
- Harmful drinking**; AUDIT; Drug-dependent patients 45, 157
- Healthy subjects**; Addiction Research Center Inventory (ARCI); Amphetamine; Reliability; Sensitivity; Specificity; ROC analysis 45, 177
- Heroin**; Naltrexone; Treatment; Overdose; Mortality; Opioids 45, 131
- History**; Nitrous oxide; Reinforcing; Choice; Subjective; Mood; Psychomotor; Alcohol; Behavior; Human 45, 63
- Human**; Nitrous oxide; Reinforcing; Choice; Subjective; Mood; Psychomotor; Alcohol; Behavior; History 45, 63
- Illicit drugs**; Family structure; Adolescents; Smoking; Alcohol; Personality 45, 121
- Inhalation**; Alternative reinforcer; Behavioral economics; Buprenorphine; Cocaine; Rhesus monkeys; Saccharin; Self-administration; Smoking 45, 21
- LEAD procedure**; Diagnostic validity; Substance abuse 45, 93
- Less-than-daily-dosing**; Buprenorphine; Opioid antagonists; Antagonist-precipitated withdrawal; Physical dependence; Spontaneous withdrawal 45, 81
- Liability**; Drug abuse; Etiology; Behavioral self-regulation; Child development 45, 165
- Marijuana**; Secondary analysis; Alcohol; Gateway drug; Prevention efforts 45, 185
- Marijuana use**; Cannabinoid; Dependence 45, 1
- Meperidine**; Morphine; β -Funaltrexamine; Naltrexone; Response-rate; Fixed-ratio schedule; Squirrel monkey 45, 197
- Metoclopramide**; Alcoholism; Amenorrhea; Prolactin; TRH 45, 115
- Monoamine oxidases**; Dependent smokers; Past history of depression; Withdrawal symptoms 45, 31
- Mood**; Nitrous oxide; Reinforcing; Choice; Subjective; Psychomotor; Alcohol; Behavior; History; Human 45, 63
- Morphine**; ATP-gated potassium channels; Tolerance; Glyburide binding; CNS 45, 47
- Morphine**; Meperidine; β -Funaltrexamine; Naltrexone; Response-rate; Fixed-ratio schedule; Squirrel monkey 45, 197
- Mortality**; Naltrexone; Heroin; Treatment; Overdose; Opioids 45, 131
- Naltrexone**; Heroin; Treatment; Overdose; Mortality; Opioids 45, 131
- Naltrexone**; Meperidine; Morphine; β -Funaltrexamine; Response-rate; Fixed-ratio schedule; Squirrel monkey 45, 197
- Nitrous oxide**; Reinforcing; Choice; Subjective; Mood; Psychomotor; Alcohol; Behavior; History; Human 45, 63
- Opioid antagonists**; Buprenorphine; Less-than-daily-dosing; Antagonist-precipitated withdrawal; Physical dependence; Spontaneous withdrawal 45, 81
- Opioids**; Naltrexone; Heroin; Treatment; Overdose; Mortality 45, 131
- Outcome**; Pregnancy; Drug dependence; Treatment; Cost-Effectiveness 45, 105
- Overdose**; Naltrexone; Heroin; Treatment; Mortality; Opioids 45, 131
- Panic**; Benzodiazepines; Alprazolam; Anxiety; Reinforcement; Self-administration; Self-medication 45, 143
- Past history of depression**; Dependent smokers; Monoamine oxidases; Withdrawal symptoms 45, 31
- Personality**; Family structure; Adolescents; Illicit drugs; Smoking; Alcohol 45, 121

- Physical dependence;** Buprenorphine; Less-than-daily-dosing; Opioid antagonists; Antagonist-precipitated withdrawal; Spontaneous withdrawal 45, 81
- Pregnancy;** Drug dependence; Treatment; Cost-Effectiveness; Outcome 45, 105
- Prevention efforts;** Secondary analysis; Marijuana; Alcohol; Gateway drug 45, 185
- Prolactin;** Alcoholism; Amenorrhea; Metoclopramide; TRH 45, 115
- Psychomotor;** Nitrous oxide; Reinforcing; Choice; Subjective; Mood; Alcohol; Behavior; History; Human 45, 63
- Reinforcement;** Benzodiazepines; Alprazolam; Anxiety; Panic; Self-administration; Self-medication 45, 143
- Reinforcing;** Nitrous oxide; Choice; Subjective; Mood; Psychomotor; Alcohol; Behavior; History; Human 45, 63
- Reliability;** Addiction Research Center Inventory (ARCI); Healthy subjects; Amphetamine; Sensitivity; Specificity; ROC analysis 45, 177
- Reliability;** Diagnosis; SCID; DSM-III-R 45, 13
- Reliability;** Drug dependence; Self reports 45, 55
- Replacement/substitution therapy;** Cocaine; Self-administration; Drug reinforcement; Agonists; Rhesus monkeys 45, 71
- Response-rate;** Meperidine; Morphine; β -Funaltrexamine; Naltrexone; Fixed-ratio schedule; Squirrel monkey 45, 197
- Rhesus monkeys;** Alternative reinforcer; Behavioral economics; Buprenorphine; Cocaine; Inhalation; Saccharin; Self-administration; Smoking 45, 21
- Rhesus monkeys;** Cocaine; Self-administration; Replacement/substitution therapy; Drug reinforcement; Agonists 45, 71
- ROC analysis;** Addiction Research Center Inventory (ARCI); Healthy subjects; Amphetamine; Reliability; Sensitivity; Specificity 45, 177
- Saccharin;** Alternative reinforcer; Behavioral economics; Buprenorphine; Cocaine; Inhalation; Rhesus monkeys; Self-administration; Smoking 45, 21
- SCID;** Reliability; Diagnosis; DSM-III-R 45, 13
- Secondary analysis;** Marijuana; Alcohol; Gateway drug; Prevention efforts 45, 185
- Self-administration;** Alternative reinforcer; Behavioral economics; Buprenorphine; Cocaine; Inhalation; Rhesus monkeys; Saccharin; Smoking 45, 21
- Self-administration;** Benzodiazepines; Alprazolam; Anxiety; Panic; Reinforcement; Self-medication 45, 143
- Self-administration;** Cocaine; Replacement/substitution therapy; Drug reinforcement; Agonists; Rhesus monkeys 45, 71
- Self-medication;** Benzodiazepines; Alprazolam; Anxiety; Panic; Reinforcement; Self-administration 45, 143
- Self reports;** Drug dependence; Reliability 45, 55
- Sensitivity;** Addiction Research Center Inventory (ARCI); Healthy subjects; Amphetamine; Reliability; Specificity; ROC analysis 45, 177
- Smoking;** Alternative reinforcer; Behavioral economics; Buprenorphine; Cocaine; Inhalation; Rhesus monkeys; Saccharin; Self-administration 45, 21
- Smoking;** Family structure; Adolescents; Illicit drugs; Alcohol; Personality 45, 121
- Specificity;** Addiction Research Center Inventory (ARCI); Healthy subjects; Amphetamine; Reliability; Sensitivity; ROC analysis 45, 177
- Spontaneous withdrawal;** Buprenorphine; Less-than-daily-dosing; Opioid antagonists; Antagonist-precipitated withdrawal; Physical dependence 45, 81
- Squirrel monkey;** Meperidine; Morphine; β -Funaltrexamine; Naltrexone; Response-rate; Fixed-ratio schedule 45, 197
- Subjective;** Nitrous oxide; Reinforcing; Choice; Mood; Psychomotor; Alcohol; Behavior; History; Human 45, 63
- Substance abuse;** LEAD procedure; Diagnostic validity 45, 93
- Substance dependence;** Alcohol; Benzodiazepine; Caffeine; Cigarette smoking 45, 207
- Δ^9 -THC;** Anandamide; CP55,940; Dynorphins; Tolerance 45, 39
- Tolerance;** Anandamide; Δ^9 -THC; CP55,940; Dynorphins 45, 39
- Tolerance;** Morphine; ATP-gated potassium channels; Glyburide binding; CNS 45, 47
- Treatment;** Naltrexone; Heroin; Overdose; Mortality; Opioids 45, 131
- Treatment;** Pregnancy; Drug dependence; Cost-Effectiveness; Outcome 45, 105
- TRH;** Alcoholism; Amenorrhea; Prolactin; Metoclopramide 45, 115
- Withdrawal symptoms;** Dependent smokers; Past history of depression; Monoamine oxidases 45, 31



